Scientists at King Abdullah University of Science and Technology have achieved a major scientific breakthrough by developing nanoscale particles capable of functioning as miniature “drug factories” inside living cells, opening the door to a new generation of highly targeted medical treatments.
The research team successfully engineered tiny particles able to transport six different proteins into living cells, where the proteins work together in sequence to produce violacein, a bioactive compound currently being studied for potential therapeutic applications.
Researchers believe the innovation could eventually allow medicines to be produced directly inside diseased tissues instead of circulating throughout the entire body, potentially reducing side effects and improving treatment precision.
The study, published in Advanced Materials, combines nanotechnology, bioengineering, and materials science to address one of modern medicine’s most difficult challenges: delivering multiple functional proteins into living cells simultaneously.
To achieve this, scientists used porous sponge-like structures known as metal-organic frameworks, or MOFs, designed to carry proteins and function like synthetic organelles that mimic natural cellular behavior.
Once inside mammalian cells, the proteins remained biologically active and worked together to convert a simple amino acid into violacein directly within the cell.
Researchers described the achievement as the first successful “protein pathway transplant” inside living cells and one of the most complex multiprotein delivery systems ever introduced into human cells.
Senior research scientist Raik Grunberg described the project as a scientific “moonshot,” explaining that delivering even a single protein into a living cell is extremely challenging, while transporting an entire coordinated protein system represents a significant leap forward.
Professor Niveen Khashab said the team overcame major technical barriers after conventional materials caused proteins to lose their activity, eventually developing a more porous and flexible structure that preserved protein function inside cells.
Scientists believe the technology could eventually lead to programmable therapies tailored to specific diseases, including cancer, genetic disorders, and complex inflammatory conditions.
Although the research remains in its early stages and still requires extensive testing before clinical application, the KAUST team plans to move toward animal trials as part of ongoing efforts to explore the system’s therapeutic potential.
The breakthrough highlights Saudi Arabia’s growing role in advanced scientific research and innovation, with KAUST continuing to play a major role in supporting future technologies under the goals of Saudi Vision 2030.
